Overall survival and second primary malignancies in men with metastatic prostate cancer.
BACKGROUND:Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC treatments may be associated with side effects, including second primary malignancies (SPM). There is limited information on the incidence of SPM among men with bone metastatic PC (mPC) and among men...
Main Authors: | Juha Mehtälä, Jihong Zong, Zdravko Vassilev, Gunnar Brobert, Montse Soriano Gabarró, Pär Stattin, Houssem Khanfir |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0227552 |
Similar Items
-
Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
by: Yanina Balabanova, et al.
Published: (2022-02-01) -
Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies
by: Vora P, et al.
Published: (2016-08-01) -
Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe)
by: David Thurtle, et al.
Published: (2020-06-01) -
Prescription-based prediction of baseline mortality risk among older men.
by: Rolf Gedeborg, et al.
Published: (2020-01-01) -
Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network
by: Lucía Cea Soriano, et al.
Published: (2018-04-01)